BRAF and neoplasm: The majority of rearrangements were KIAA1549-BRAF rearrangements (n = 47; 85%), with only one tumor each harboring BCAS1, CCDC6, GIT2, or PTPRZ11 as a fusion partner (Fig. 1b).